The viral ribonucleotide reductase (rR)-defective herpes simplex type-1 (HSV-1) virus (hrR3) has been shown previously to preferentially replicate in and kill tumor cells. This selectivity is associated with tumor cell up-regulation of mammalian rR. Ionizing radiation (IR) is currently used in the therapy of many malignancies, including glioblastoma, cervical carcinoma, and pancreatic carcinoma. IR has been shown to up-regulate mammalian rR in tumor cells and appears to increase the efficacy of at least one non-rR-deleted HSV-1 strain in an in vivo tumor model. Here, we test the hypothesis that a single therapeutic radiation fraction will increase the replication and toxicity of hrR3 for malignant cell lines in vitro. PANC-1 pancreatic carcinoma, U-87 glioblastoma, and CaSki cervical carcinoma cell lines were treated with varying doses of IR and subsequently infected with hrR3 or KOS (wild-type HSV-1 strain). Cell survival was then measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay and trypan blue exclusion cytometry. At 72 hours posttreatment, irradiation with 2 Gy reduced survival from 100% to 76% in noninfected cells, from 61% to 48% in KOS-infected cells, and from 39% to 27% in hrR3-infected PANC-1 cells. As such, analysis of variance indicated that the toxicity of the two modalities was additive. Similar additivity was seen in U-87 MG and CaSki cells. Absolute survival of hrR3-infected or KOS-infected PANC-1 cells decreased as a function of time after treatment (24 -72 hours) and multiplicity of infection (MOI) (0.05-5.0). However, the relative decrease in survival with the addition of IR to hrR3 or KOS in PANC-1 cells was not markedly affected by altering MOI (0.05-5.0), time (24 -72 hours), radiation dose (2-20 Gy), or cell culture conditions (confluent/growth arrested). We used fluorescence-activated cell sorter analysis with the cationic lipophilic dye DiOC 6 to quantify a reduction in mitochondrial membrane potential that is associated with apoptosis. Fluorescence-activated cell sorter analysis indicated increased apoptosis in both hrR3-and IR-treated cells at 48 -72 hours, with hrR3 alone producing the most induction. Viral yields from PANC-1 cells after irradiation and infection were examined. No significant differences were seen between irradiated and nonirradiated cells in viral replication, with hrR3 producing single-step titers of 3.1 Ϯ 0.9 ϫ 10 5 and 4.0 Ϯ 1.2 ϫ 10 5 plaque-forming units/mL in nonirradiated and irradiated cells. Thus, complementary toxicity was seen between IR and hrR3 or KOS, regardless of cell type, time, MOI, IR dose, or culture conditions, without evidence of augmented apoptosis or viral replication.
R adiation therapy plays a primary role in the treatment of many tumors, including pancreatic carcinoma, cervical carcinoma, and high-grade gliomas such as glioblastoma multiforme. In the cases of pancreatic adenocarcinoma and glioblastoma multiforme, radiation therapy clearly extends survival but is rarely curative, with most patients dying of progressive localized disease. Ionizing radiation (IR) is commonly used in combination with other modalities, such as surgery and or chemotherapy. Each therapeutic modality has its own mechanism and profile of selective elimination of tumor cells as opposed to normal cells. Therapies are combined such that additive or synergistic toxicity to tumor cells is maximized, whereas toxicity to normal tissue is mini-mized. If each modality reaches a point at which its toxicity to vital normal tissues is limiting and overlaps with other existing agents, cure is not achieved. Gene therapy offers a novel means of delivering selective, synergistic, and nonoverlapping toxicity to tumor cells. Indeed, the activated prodrug metabolites generated by a number of the most commonly used anti-neoplastic transgenes, including herpes simplex virus type-1 (HSV-1) thymidine kinase (tk) and Escherichia coli cytosine deaminase, have demonstrated synergy with IR. 1, 2 The HSV-1 oncolytic viral vector hrR3 has intrinsic selective toxicity for tumor cells and has been employed therapeutically against experimental cancers.
3,4 This oncolytic viral vector is defective for the large subunit of HSV-1 ribonucleotide reductase (rR) (ICP6 or UL39). 5 Its replication is thus complemented by tumor cells but not postmitotic normal tissue cells, presumably because the former overexpress mammalian rR (mRR), thus providing the deoxynucleotides required for efficient viral DNA synthesis. 6 In fact, an association between overexpression of mRR and viral replication has been shown. 7, 8 Advani et al 9 have previously shown an advantage with radiation therapy for viral replication and tumor response with another modified HSV-1 vector (defective for viral ␥34.5 but not rR) in in vivo murine tumor models. Kuo and Kinsella 10 have shown that IR increases mRR levels in tumor cells. This raises the question as to whether IR could further sensitize cells to replicative cytotoxicity by an rR-defective HSV-1 vector. To our knowledge, rR-deleted vector-radiation interactions and in vitro interactions with other HSV-1 vectors have not been investigated. Evaluating the combination of an rR-deleted HSV-1 vector with IR is even more relevant, as a number of such vectors will likely soon enter clinical trials for malignancies that are commonly treated with radiation therapy. That the tk carried by hrR3 and other HSV-1 vectors preferentially activates several radiation-sensitizing prodrugs provides additional potential for synergy. 1 Thus, we sought to test whether using hrR3 in combination with IR would increase the in vitro replication and cytotoxicity of hrR3, as well as characterize the mechanisms of the interaction. We used the wild-type (wt) HSV-1 strain KOS as a control. We chose the human pancreatic adenocarcinoma cell line PANC-1 as the primary experimental model, but also examined glioblastoma (U-87 MG) and cervical carcinoma (CaSki) cell lines to test how well the results could be generalized.
MATERIALS AND METHODS

Cell lines
PANC-1 human pancreatic carcinoma cells, U-87 MG human glioblastoma cells, and CaSki human cervical carcinoma cells were obtained from the American Type Culture Collection (Manassas, Va). Cells were maintained in either RPMI 1640 (for CaSki cells) or Dulbecco's minimum essential medium (for U-87 and PANC-1 cells) supplemented with 10% fetal calf sera (FCS), 100 U/mL penicillin, and 100 g/mL streptomycin (Life Technologies, Grand Island, NY). All cell cultures were incubated at 37°C in a 5% CO 2 incubator.
Viral vector preparation and titering
The ICP6-defective HSV-1 virus hrR3 was provided by Dr. Sandra Weller (University of Connecticut Medical School, Farmington, Conn) and the wt HSV-1 virus KOS was provided by Dr. David Knipe (Harvard Medical School, Boston, Mass). hrR3 contains an insertional mutation of the E. coli lacZ cDNA into the ICP6 locus, thus generating an ICP6:LacZ fusion protein that does not possess rR activity. 5 Virus was grown in Vero cells and titrated as described previously. 5 Briefly, confluent Vero cells were infected with virus at a multiplicity of infection (MOI) of 1 in complete medium (Dulbecco's modified Eagle's medium, 10% FCS, 100 U/mL penicillin, and 100 g/mL streptomycin). After 24 -48 hours, cells and supernatant were harvested, exposed to three freezethaw cycles and centrifuged at 1400 ϫ g for 6 minutes. Supernatant was titrated onto confluent Vero cells in sequential dilutions and incubated at 37°C for 90 minutes. The culture was then overlayed with 1% agarose (SeaPlaque; FMC Bioproducts, Philadelphia, Penn) in complete media and returned to the 37°C incubator. Additional medium was added on the second day. Plaques were counted 3 days later, and the titer was determined.
Irradiation
Cells were irradiated using a 137 Cs radiation unit at a dose rate of 2.77 Gy/minute (Mark 7; Sheppard, Los Angeles, Calif). Calibration was carried out using Fricke dosimetry. Total radiation doses were 0, 2, 6, 10, or 20 Gy delivered as a single fraction.
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay A total of 3000 cells/well were plated onto 96-well plates. On the following day, they were irradiated with doses ranging from 0 Gy to 20 Gy. After 2 hours, the mean cell number was determined in random control wells and virus was added to sample wells at MOIs ranging from 0.05 to 5 (results presented from a MOI of 5 unless otherwise specified). Cells were incubated at 37°C. At varying times after infection, 20 L of 0.5 mg/mL thiazolyl blue (MTT; Sigma, St. Louis, Mo) was added to each well and cells were incubated at 37°C for 3.5 hours to allow formazan crystals to form. Cells were then spun at 3000 rpm for 5 minutes, and the medium was replaced with 50 L of dimethylsulfoxide. The optical density (OD) of each well was measured using an automated plate reader (Molecular Devices, Palo Alto, Calif) at a wavelength of 550 nm with a reference wavelength of 650 nm. Results were confirmed to fall within the linear portion of the titrated cell number:OD curves. All experiments were performed in quintuplicate.
Trypan blue exclusion viability assay
Surviving cell numbers after treatment were also determined by trypan blue exclusion manual cytometry. Cells were plated at 2 ϫ 10 4 cells/well in 24-well plates. They were irradiated with 0 or 2 Gy on the following day. Virus was added at a MOI of 1. At 3 days postinfection, cells were trypsinized, harvested, diluted 1/20 in trypan blue, and applied to a glass hemocytometer; viable cells were counted using light microscopy.
Survival fractions
The percentage of cell survival was calculated as the OD from MTT assays or as the number of surviving cells from cytometry assays of treated samples divided by nontreated samples. Relative survival was calculated as the survival fraction of irradiated cells divided by the survival fraction of nonirradiated cells within a treatment group.
Confluent/growth-arrested cells
Confluent/growth-arrested cells were produced by plating cells at near confluence in 96-well plates (2 ϫ 10 4 cells/well) in complete media and were grown for 5 days with daily medium replacement. Complete medium was then replaced with low serum media containing only 0.2% FCS, and cells were grown for an additional 2 days. Cells were then irradiated with varying doses and infected with virus at a MOI of 0.5-5.0 as described above. Low serum media were replaced with the addition of virus. MTT assays were conducted at 72 hours postinfection as described above.
Fluorescence-activated cell sorting (FACS) analysis
Quantification of apoptosis by propidium iodide (PI) and DiOC 6 staining with FACS analysis was carried out as described previously. [11] [12] [13] Cells were plated in 60-mm Petri dishes at 8 ϫ 10 4 cells/plate. On the following day, they were irradiated with 2 or 6 Gy; after 2 hours, virus was added at a MOI of 5. At 0.5, 1, 3, 6, 24, 48, and 72 hours after viral infection, cells were collected, pelleted by centrifugation, resuspended in phosphate-buffered saline (PBS) containing 50 mg/mL PI and 20 nM DiOC-6 (Molecular Probes, Sunnyvale, Calif), and analyzed by FACS (FL-3 channel).
Viral yield
A total of 3 ϫ 10 4 cells/well were plated onto 12-well plates. On the following day, cells were irradiated with 0, 2, or 20 Gy. Mean cell number was determined, and virus was added at a MOI of 2. Cells and media were harvested and titrated onto Vero cell monolayers at the stated times after infection as described above. Single-step, 16-hour viral titers were determined using the agarose overlay method as described above. hrR3 time course titers were quantified using 5-bromo-4-chloro-3-indolyl ␤-D-galactoside staining for LacZ expression. Experiments were performed in triplicate wells
Statistical methods
The percentage of survival relative to the mean for the controls (no radiation, no virus) at each timepoint (24, 48, and 72 hours) was computed for each experimental observation. Survival rates by time, with and without radiation and with different viral MOIs, were assessed in an overall analysis of variance (ANOVA) that included effect interactions. A significant two-way interaction of radiation with virus would be an indicator of a departure from additivity of effects, suggesting synergy if cell survival was significantly reduced when both radiation and virus were present compared with either separately.
The same general analytic approach was used to evaluate trypan blue assay results with and without hrR3 virus and with and without radiation separately in three cell lines (U-87, CaSki, PANC-1) and to evaluate another set of experiments using confluent/growth-arrested cells. Finally, a one-way ANOVA was used to examine the effect of radiation dose on viral yields on human pancreatic cancer cells.
RESULTS
Dependence of the absolute survival of PANC-1 cells upon hrR3 and KOS MOI, radiation, and time after treatment To characterize the time course and viral dose (MOI) effects on viral cytotoxicity, MTT assays were performed on pancreatic carcinoma (PANC-1) cells irradiated or mock-irradiated and subsequently infected with either hrR3 or KOS vector. For both types of viruses used (hrR3 and KOS), the overall main effects for time, virus MOI, and IR were highly significant (P Ͻ .0001). Cell survival decreased with increasing time, with IR treatment, and with increasing MOI. Toxicity was timedependent, with the greatest effects seen at 72 hours posttreatment ( Fig 1A) . Moreover, there were significant interactions of time with IR and time with MOI (both P Ͻ .0001), indicating differences in the effect of IR or virus at different points in time. At 24 hours, IR increased cell killing, but all doses of virus (hrR3 or KOS) were about equally lethal compared with control. At 48 hours, the highest MOI of either virus appeared to affect survival, and radiation had an additional effect for both types of virus. At 72 hours (Fig 1B) , there was a clear MOI effect for both virus types; when IR was added, survival was further reduced.
Interaction of hrR3 and KOS viral and radiation cytotoxicity
To investigate the effect of interactions between radiation and viral therapy on cell survival, data from MTT assays performed on PANC-1 cells were further analyzed. In general, ANOVA indicated that cell survival was decreased with IR and with the addition of either virus (P Ͻ .0001), but there was no evidence of synergy (hrR3, P ϭ .0995; KOS, P ϭ .2351), although IR nearly always further reduced cell survival. As seen in Figure  1A , at 72 hours posttreatment with a MOI of 5, hrR3 alone resulted in 38.6 Ϯ 1.6% survival; a total of 2 Gy IR alone resulted in 75.9 Ϯ 3.5% survival of PANC-1 cells. The combination of hrR3 and IR resulted in survival of 27.2 Ϯ 2.7%, (11.4% lower than hrR3 alone), thus producing a relative survival of 0.69 compared with hrR3 alone. This is similar to the aforementioned relative survival of 0.76 that IR produces in PANC-1 cells alone. A similar result was obtained when PANC-1 cells were treated with KOS or with both KOS and IR, with survivals of 61.4 Ϯ 1.9% and 48.2 Ϯ 2.4%, producing a relative survival of 0.79.
Effects of variations in MOI, incubation time, radiation dose, or cell culture conditions on relative survival with combined treatment To confirm that an improvement in the relative effect of combined treatment could not be obtained through variation of experimental conditions, hrR3 toxicity with and without IR in PANC-1 cells was examined using MTT assays with varied conditions. As described above, ANOVA indicated additivity at best across conditions, including cells treated with hrR3 at MOIs of 0, 0.05, 0.5, or 5 ( Fig 1B) and assayed at 24, 48, and 72 hours ( Fig  1A) PANC-1 cells, radiation did not significantly enhance cell killing, but the presence of either virus did reduce survival (P Ͻ .0001). For CaSki cells, both radiation and virus significantly reduced cell survival (both P Ͻ .0001), but there was no significant interaction between radiation and virus (hrR3, P ϭ .1062; KOS, P ϭ .5188).
Trypan blue viability assays to confirm MTT assay results
To confirm the above findings using alternate methodologies, viral and IR toxicity was also assessed using trypan blue exclusion. Similar trends in toxicity and relative survival were observed. At 72 hours postinfection, viability in hrR3-infected PANC-1 cells for irradiated cells compared with nonirradiated cells was re- duced from 13% to 9% (relative survival ϭ 0.69). Radiation alone resulted in 63% viability (relative survival of 0.63). ANOVA again indicated additive toxicity (P ϭ .1229)
Interactions of viral and radiation therapy in other malignant cell lines Similar results were seen using trypan blue exclusion viability assays in other cell lines. At 72 hours postinfection, viability in nonirradiated cells compared with irradiated cells was reduced from 43% to 15% in U-87 cells and from 9% to 1.6% in CaSki cells. IR alone resulted in 30% and 19% viability in the U-87 and CaSki cells, respectively, producing relative survivals of 0.30 and 0.34 for control and hrR3-infected U-87 cells and 0.19 and 0.17 for control and hrR3-infected CaSki cells. The differences in U-87 cells are not significant (P ϭ .2097). Although a statistically significant interaction was indicated in CaSki cells at P ϭ .026, the difference in relative survival values (0.19 compared with 0.17) is not large. Furthermore, no consistent trend in interactive effects was seen in CaSki cells using MTT assays (data not shown).
FACS analysis to quantify apoptosis
To investigate a potential mechanism of viral and IR effects, quantification of apoptosis by DiOC 6 and PI staining with FACS analysis was carried out on PANC-1 cells treated with radiation, virus, or a combination of the two. Figure 2 , A and B, illustrates the results seen with FACS analysis. There was no difference in apoptosis between control and treatment groups at early timepoints (Ͻ6 hours). By 48 and 72 hours, both IR and virus induced DiOC 6 mitochondrial membrane permeability associated with apoptosis. The greatest percentage of cells undergoing apoptosis was seen in the hrR3 only group, with 42% and 58% at 48 and 72 hours. The addition of IR to hrR3 produced less apoptosis than hrR3 alone, but more than IR alone. The fraction of apoptotic cells induced increased with IR dose from 2 Gy to 6 Gy.
Viral yields of hrR3 or wt herpes virus from PANC-1 cells
A single-step growth analysis was employed to determine viral yields after a 16-hour infection period with hrR3 or KOS in irradiated or nonirradiated PANC-1 cells. These were not significantly different with hrR3 or KOS wt HSV-1 (Table 1 ) (P ϭ .6213 and P ϭ .7279) regardless of IR doses up to 20 Gy. No differences in titers from irradiated compared with nonirradiated cells appeared over a 72-hour time course (Fig 3) .
DISCUSSION
In this study, we demonstrate additive toxicity between two HSV-1 vectors and IR. This lends further support for continued progress into clinical investigations of such combined modality therapy in such therapeutically challenging diseases as localized pancreatic adenocarcinoma, high-grade glioma, and locally advanced cervical carcinoma. As in other currently used combined modality regimens, each agent may contribute a unique selective toxicity to the tumor without overlapping host toxicity, thus allowing additional palliation or cures. HSV-1 vectors have demonstrated antitumoral effects in murine tumor models for a variety of malignant pathologies and cell types, but regression or stabilization of disease as opposed to cure has been most commonly seen.
4,14 -16 Advani et al 9 have actually demonstrated apparent supra-additive IR effects on both viral replication and tumor growth in an in vivo murine high-grade glioma model using the ␥34.5 deletion mutant R3616.
That IR produced neither a supra-additive relative increase in hrR3 toxicity nor viral yield, either intrinsically or compared with KOS, in the assays described above requires explanation in the face of the reports by Advani et al 9 and theoretical support through increased mRR activity of up to 4-fold by IR. 10 The first consideration is of course that experimental conditions or assays were not appropriate. This was addressed through variation of conditions and assay techniques without significant change in outcome. MOIs from 0.05 to 5 and posttreatment incubation times from 24 hours to 7 days were evaluated. Radiation doses were tested from a 2 Gy standard clinical daily treatment dose up to 20 Gy, which approaches the maximum clinical dose used in stereotactic radiosurgery procedures. Markedly different malignant cell lines were tested. Finally, the growth-arrested/confluent conditions in which Kuo and Kinsella 10 demonstrated the highest rR induction were replicated. Several common and accepted cytotoxicity measures including MTT, trypan blue cytometry and DiOC 6 -FACS apoptosis assays were tested. Automated Coulter Counter-based cytometry (Coulter, Hialeah, Fla) also produced similar results (data not shown). Another possible explanation is that hrR3 replication is not dependent upon mRR levels or other IR-induced changes within the range produced, in that above a threshold mRR level, the virus replicates and kills cells at its maximum potential based on other rate-limiting steps such as viral translation, protein translation, structural assembly, negative feedback, or cellular response. Viral DNA synthesis in infected cells may already be provided with sufficient deoxynucleotides from up-regulated mRR; additional radiation-induced increases in mRR do not result in concomitant increases in viral DNA synthesis and replication. Further experiments comparing the replication of mutant viruses in quiescent tumor and normal cells before and after radiation may provide additional evidence supporting or refuting the latter possibility. It is also possible that the deoxynucleotides used by hrR3 for viral DNA synthesis are not actually provided through mRR but through other cellular pathways not affected by irradiation. Consideration may further be given to the differential effects of radiation on the small versus the large subunit of mRR. Although IR has been seen to increase the levels of mRR enzyme activity, this is likely to be principally accomplished through increased protein levels of the small subunit, 10 thus potentially failing to provide augmented complementation of the large subunit viral defect. Virus deleted for the U L 40 gene encoding the small subunit might produce more interaction with IR.
The most apparent explanation for the lack of measurable in vitro synergistic interactions between hrR3 or KOS and IR in the face of the in vivo results produced with ␥34.5 deletion mutants is that they are different vectors that benefit from variations in different genes which respond differently to IR. Our results with hrR3 and KOS imply that IR does not induce intracellular conditions that are generally favorable to herpes viral replication, other than those related to the ␥34.5 deletion, which have been theorized to result from IR induction of ␥34.5 complementing cellular GADD34 as an explanation for the synergistic effects seen with R3616. 9 Different models and radiation doses were also used; however, we did test a variety of cell lines and doses, including evaluation of the U-87 MG line used the R3616 experiments. But it is also possible that the complicated and interactive nature of the in vivo model is responsible. Although, the experiments were performed in nude mice with minimal residual specific immune function, it is possible that the radiation given resulted in additional local immune suppression secondary to leukocyte or other effector cell toxicity, allowing for unattenuated viral replication and spread. The radiation doses delivered were also high enough to produce clonogenic sterilization of tumor cells, and thus the observed flat tumor growth curves in non-HSV-1-treated tumors. The application of an oncolytic HSV-1 vector might then lyse the clonogenically sterile cells eliciting the subsequent observed measurable tumor regressions. This would be in contrast to growing tumors, which have been seen to have the capacity to outpace viral replication and eventually progress through treatment with replicating HSV-1 vectors. 9 The in vivo/in vitro comparison with regard to growth is additionally complicated by the ability of virus in culture to rapidly diffuse throughout the media to infect and kill all cells, as opposed to a solid tumor where diffusion through tissue is limited, particularly to viable cells that have migrated into normal tissues. 17, 18 Of further interest, the role of cytotoxic pathways, such as apoptosis in IR-HSV-1 interactions, has not been characterized previously. IR has a demonstrated ability to induce apoptosis, and this has been seen to peak at Ն48 hours in many cell lines. 19, 20 The above FACS analyses indicate that induction of increased mitochondrial membrane permeability, a surrogate for apoptosis, may play a late role in the cytotoxicity of HSV-1 and IR, but that the two treatments do not complement each other. In fact, hrR3 alone produced more than the combination, possible secondary to inhibition by IR or a relative increase in death through nonapoptotic mechanisms. In comparison, at early timepoints, neither HSV-1 nor IR has a significant effect on apoptosis. These findings are consistent with other published research on the interaction of HSV-1 with apoptotic pathways. Specifically, Galvan et al 21 and Leopardi et al 22 found that HSV-1 infection actually protects cells from some inducers of apoptosis at early timepoints, and that this activity appears to map to the ICP4 (␣4) and U S 3 gene products. This may partially explain the lack of synergistic toxicity in the face of a theoretical advantage. It may also explain to some degree the more favorable results of in vivo studies in which other factors such as interferon, tumor necrosis factor-␣, and T-cell interactions could induce additional apoptosis of infected cells. 21, 23 These considerations provide another fertile ground for further investigation, as manipulation of viral apoptotic activating and repressing mechanisms could potentially be exploited for further therapeutic benefit, such as increased cytotoxicity or decreased viral dissemination.
The demonstrated efficacy of IR in combination with hrR3 and KOS leads to consideration of incorporating transgenes with known radiation sensitization capabilities, as well as exploitation of the intrinsic HSV-1 tk activity of HSV-1 vectors. tk has been shown to activate acyclovir and 5-(2-bromovinyl)-2Ј-deoxyuridine to radiation sensitizers that have synergistic in vitro and in vivo antitumoral effects with IR.
24 E. coli cytosine deaminase converts 5-fluorocytosine into the radiation sensitizer 5-fluorouracil, and has been used successfully in in vitro and in vivo models, both alone and in combination with tk.
1 Furthermore, the hrR3-based HSV-1 vector rRp450, carrying the p450 CYP2B1 transgene combined with its prodrug cyclophosphamide, has demonstrated antitumoral activity against 9L gliosarcoma models 8 and is being investigated in combination with IR by our group.
In summary, the combination of IR and hrR3 or KOS results in complementary toxicity, but supra-additive interactions were not seen. IR neither aids nor impedes viral replication. HSV-1 infection and IR induce apoptosis at late timepoints, but do not augment each other. We plan to continue to develop a translational approach to hrR3 based and other HSV-1 vectors into clinical combined modality regimens. Depending upon in vitro outcomes using rRp450 combined with cyclophosphamide, ganciclovir, and IR, we will likely test this regimen in a 9L rat gliosarcoma model and/or a nude mouse U-87 xenograft model. We are also considering investigations of normal glial cell cultures in response to combined treatment to gain insight into possible normal tissue sequelae. These issues are of particular import given the high probability of clinical utilization of HSV-1 vectors, particularly rR-deleted vectors, in combination with therapeutic radiation secondary to transgene synergy and complementary toxicity. 
